Sea Mild Biotechnology Co., Ltd.

As of June 30, 2026, Sea Mild Biotechnology Co., Ltd. carries a market capitalization of 173.78M, placing it among publicly traded companies globally. Its enterprise value stands at 220.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sea Mild Biotechnology Co., Ltd. has 19.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sea Mild Biotechnology Co., Ltd. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Sea Mild Biotechnology Co., Ltd.'s stock has declined approximately 17.27% over the past 52 weeks. The 50-day moving average sits at 8.36, while the 200-day moving average is 9.18.

As of June 30, 2026, Sea Mild Biotechnology Co., Ltd. holds 75.07M in cash and equivalents against 121.46M in total debt, resulting in a net debt position of 25.47M. Total book value stands at 113.72M, with working capital of 72.10M providing operational flexibility.

Sea Mild Biotechnology Co., Ltd.'s most recent stock split took place on February 1, 2021 with a 13:10 split ratio.